Kano

KRas

KRas is a protein that in humans is encoded by the KRAS gene. It is a member of the Ras family of GTPases, which are involved in transmitting signals within cells (cellular signal transduction). When mutated, KRas is often involved in the development of cancer, making it a significant focus of cancer research.

Structure and Function

KRas is a small GTPase, which means it can bind to and hydrolyze guanosine triphosphate (GTP). It acts as a molecular switch in the cell, cycling between an active GTP-bound state and an inactive GDP-bound state. In its active form, KRas interacts with a variety of downstream effectors to regulate cell proliferation, differentiation, and survival.

Gene and Protein Structure

The KRAS gene is located on chromosome 12p12.1. It encodes a protein of 188 amino acids. The protein has several important regions, including the GTP-binding domain and the effector domain, which are critical for its function.

Isoforms

KRas has two main isoforms, KRas4A and KRas4B, which arise from alternative splicing. These isoforms differ in their C-terminal regions, which affects their membrane localization and function.

Role in Cancer

Mutations in the KRAS gene are among the most common oncogenic alterations in human cancers. These mutations often lead to constitutive activation of the KRas protein, driving uncontrolled cell division and tumorigenesis.

Common Mutations

The most frequent mutations occur at codons 12, 13, and 61. The G12D, G12V, and G13D mutations are particularly prevalent in cancers such as pancreatic, colorectal, and lung cancer.

Mechanism of Oncogenesis

Mutant KRas proteins are locked in the GTP-bound active state, continuously activating downstream signaling pathways such as the MAPK/ERK and PI3K/AKT pathways, which promote cell growth and survival.

Clinical Implications

KRas mutations are important biomarkers for cancer diagnosis and prognosis. They also have significant implications for treatment, as tumors with KRas mutations often show resistance to certain therapies, such as EGFR inhibitors.

Targeted Therapies

Developing targeted therapies for KRas-mutant cancers has been challenging, but recent advances have led to the development of specific inhibitors, such as sotorasib, which targets the G12C mutation.

Research and Developments

Ongoing research is focused on understanding the biology of KRas and developing effective therapies. This includes efforts to target KRas directly, as well as its downstream signaling pathways.

Also see

• Ras subfamily
• GTPase
• Signal transduction
• Oncogene
• Cancer